Health
LoDoCo2: Added Steam for Colchicine as Secondary Prevention – Medscape
The benefits emerged early and continued to accrue through the trial, with no suggestion of attenuation during up to 5 years of treatment.
The anti-inflammatory drug colchicine picked up new support as secondary prevention in chronic coronary disease, cutting the risk of cardiovascular events by one third when added to standard prevention therapies in the double-blind LoDoCo2 study.
Across a median follow up of 29 months in more than 5000 patients, almost 1 in 10 patients assigned to placebo experienced the primary endpoint of cardiovascular (CV) death, myocardial infarction (MI), ischemic stroke, or ischemia-driven coronary revas…
-
Noosa News23 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News16 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General15 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News7 hours agoNew playground equipment encourages children to learn through ‘risky play’